Human IgG autoantibodies against galactose–deficient IgA1, preparation method thereof , and use thereof

Category: *Precision Health & Smart Medical

Exhibitor: NATIONAL DEFENSE MEDICAL CENTER

Booth No: N/A

Characteristic

IgA nephropathy (IgAN) is the most common glomerulonephritis. IgAN has been considered to be an autoimmune disease that features IgA immune complexes containing galactose-deficient (Gd)-IgA1 (autoantigen) bound with IgG anti-Gd-IgA1 (autoantibody). Clinically, a renal biopsy examination (to get renal tissues from a patient) is absolutely required for diagnosis of the renal disorder. However, renal biopsy involves taking an invasive route and potential complications to the patient, and this drawback might largely prevent early diagnosis and monitoring of disease progression as well for the cases. Therefore, it is clinically warranted to develop non-invasive or only minimally invasive measures for early diagnosis of IgAN. To do this, we successfully developed {1} mouse hybridoma cell line and {2} human hybridoma cell lines that produce anti-Gd-IgA1 antibodies. Importantly, these results could be obtained for further correlating with the clinical aspects of IgAN cases and develop diagnostic reagents to renew the clinical assessment protocol for the renal disorder.